Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
@article{Wit2005IsTA, title={Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?}, author={R. de Wit and M. Aapro and P. Blower}, journal={Cancer Chemotherapy and Pharmacology}, year={2005}, volume={56}, pages={231-238} }
Abstract5-HT3-receptor antagonists are the current antiemetic ‘gold standard’ for chemotherapy- and radiotherapy-induced nausea and vomiting. Interestingly, studies have shown that patients experiencing poor control of acute chemotherapy-induced nausea and vomiting with one antiemetic therapy may respond well to another agent, including a drug of the same class. This review examines pharmacological differences between the 5-HT3-receptor antagonists in order to determine potential reasons for… CONTINUE READING
38 Citations
Recent advances in antiemetics: new formulations of 5HT3-receptor antagonists
- Medicine
- Cancer management and research
- 2018
- 15
- PDF
Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics
- Medicine
- International Journal of Clinical Pharmacy
- 2010
- 51
- PDF
Does Pharmacogenomics Account for Variability in Control of Acute Chemotherapy-Induced Nausea and Vomiting with 5-Hydroxytryptamine Type 3 Receptor Antagonists?
- Medicine
- Current Oncology Reports
- 2013
- 12
Therapeutics of 5-HT3 receptor antagonists: current uses and future directions.
- Chemistry, Medicine
- Pharmacology & therapeutics
- 2011
- 59
Timing and duration of 5-HT3 receptor antagonist therapy for the prophylaxis of radiotherapy-induced nausea and vomiting: a systematic review of randomized and non-randomized studies
- Medicine
- Journal of Radiation Oncology
- 2012
- 15
- Highly Influenced
- PDF
Evolving treatment paradigms for chemotherapy-induced nausea and vomiting.
- Medicine
- Cancer control : journal of the Moffitt Cancer Center
- 2012
- 15
- PDF
5-hydroxytryptamine and the gastrointestinal tract: where next?
- Medicine
- Trends in pharmacological sciences
- 2008
- 64
References
SHOWING 1-10 OF 70 REFERENCES
5‐HT3‐Receptor Antagonists and the Cytochrome P450 System: Clinical Implications
- Medicine
- Cancer journal
- 2002
- 59
Volunteer models for predicting antiemetic activity of 5-HT3-receptor antagonists.
- Medicine
- British journal of clinical pharmacology
- 1994
- 20
Oral serotonin type 3-receptor antagonists for prevention of chemotherapy-induced emesis.
- Medicine
- American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
- 2000
- 34
- PDF
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
- Medicine
- European journal of cancer
- 2003
- 224
Consensus Proposal for 5-HT3 Antagonists in the Prevention of Acute Emesis Related to Highly Emetogenic Chemotherapy
- Medicine
- 1998
- 27
Consensus proposal for 5HT3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapy
- Medicine
- Supportive Care in Cancer
- 1998
- 53
Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2002
- 235
Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics
- Medicine
- British journal of cancer
- 2003
- 12
Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 1994
- 84
A meta-analysis comparing the efficacy of five 5-HT3-receptor antagonists (5-HT3-RAs) for acute chemotherapy induced emesis.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2004
- 8